<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655642</url>
  </required_header>
  <id_info>
    <org_study_id>VUMC 0612369</org_study_id>
    <nct_id>NCT00655642</nct_id>
  </id_info>
  <brief_title>Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED</brief_title>
  <official_title>A Randomized, Double Blind, and Placebo-Controlled Trial Comparing Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult Emergency Department.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of ondansetron, metoclopramide, and
      promethazine for the treatment of nausea in the adult emergency department population.

      We hypothesize that a single intravenous dose of ondansetron is more effective in reducing
      nausea than a single IV dose of metoclopramide, promethazine or normal saline placebo in
      undifferentiated adult emergency department patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Conditional analysis showed observed differences were significantly less than power
    calculations
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog Scale (VAS) Score for Nausea. This Was Calculated by Subtracting the Patient's Reported Score on the 30 Minute VAS From the Patient's Reported VAS Score on Their Baseline VAS.</measure>
    <time_frame>Baseline and 30 minute assessments</time_frame>
    <description>Participants independently rated their nausea severity on separate scales at the baseline and 30-minute evaluations to prevent the baseline VAS score from influencing the 30-minute mark. The VAS had the words &quot;Least Severe&quot; on the left and &quot;Most Severe&quot; on the right. The possible values range from 0 to 100mm with 0 at the &quot;Least Severe&quot; extreme and 100 at the &quot;Most Severe&quot; extreme. Investigators instructed the participant to draw a single vertical line through the point on the 100mm scale that corresponded to their nausea severity at the times of measurement (Baseline and 30 minutes).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ondansetron 4 mg intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10 mg intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Promethazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Promethazine 10 mg intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volume-matched saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter</description>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter</description>
    <arm_group_label>Metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promethazine</intervention_name>
    <description>12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter</description>
    <arm_group_label>Promethazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients age 18 or older who present to the ED with a complaint requiring
             antiemetic treatment who do not meet the exclusion criteria.

        Exclusion Criteria:

          -  Patients less than 18 years of age

          -  Unstable patients with SBP &lt; 90

          -  Patients with a stated or documented allergy to any of the study medications

          -  Patients whose nausea rating if &lt; 40 on the pretreatment VAS scale

          -  Patients who have received a commonly accepted antiemetic within the previous 24 hours

          -  Patients unwilling or unable to complete the assessment tool before and 30 minutes
             after study drug dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyler W Barrett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Barrett TW, DiPersio DM, Jenkins CA, Jack M, McCoin NS, Storrow AB, Singleton LM, Lee P, Zhou C, Slovis CM. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. Am J Emerg Med. 2011 Mar;29(3):247-55. doi: 10.1016/j.ajem.2009.09.028. Epub 2010 Mar 26.</citation>
    <PMID>20825792</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <results_first_submitted>March 21, 2011</results_first_submitted>
  <results_first_submitted_qc>April 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2011</results_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Tyler Barrett</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started March 2007 and completed October 2008. A covenience sample of all adult patients who presented to the emergency department (ED) with a complaint requiring antiemetic treatment who do not meet the exclusion criteria were considered for enrollment.</recruitment_details>
      <pre_assignment_details>Not applicable to this study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ondansetron</title>
          <description>Patients randomized to a single 2 milliliter (mL) Ondansetron 4 mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="P2">
          <title>Metoclopramide</title>
          <description>Patients randomized to a single 2 mL Metoclopramide 10 mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="P3">
          <title>Promethazine</title>
          <description>Patients randomized to a single 2 mL Promethazine 12.5mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Patients randomized to a single 2-mL isotonic sodium chloride Saline Placebo intravenous treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41">1 patient withdrawn by treating physician after consent</participants>
                <participants group_id="P2" count="40">1 patient given drug orally rather than intravenous(iv);1 patient refused iv; 1 pt lost to follow-up</participants>
                <participants group_id="P3" count="43">1 patient left the ED prior to receiving drug; 1 patient's nausea resolved prior to receiving drug</participants>
                <participants group_id="P4" count="39">1 patient's initial Visual analog scale (VAS)&lt;40; 1 patient was withdrawn by treating physician</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ondansetron</title>
          <description>Patients randomized to a single 2 milliliter (mL) Ondansetron 4 mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="B2">
          <title>Metoclopramide</title>
          <description>Patients randomized to a single 2 mL Metoclopramide 10 mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="B3">
          <title>Promethazine</title>
          <description>Patients randomized to a single 2 mL Promethazine 12.5mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Patients randomized to a single 2-mL isotonic sodium chloride Saline Placebo intravenous treatment</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.98" spread="16.895"/>
                    <measurement group_id="B2" value="38.72" spread="16.076"/>
                    <measurement group_id="B3" value="35.47" spread="16.036"/>
                    <measurement group_id="B4" value="35.44" spread="14.589"/>
                    <measurement group_id="B5" value="37.14" spread="15.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Scale (VAS) Score for Nausea. This Was Calculated by Subtracting the Patient's Reported Score on the 30 Minute VAS From the Patient's Reported VAS Score on Their Baseline VAS.</title>
        <description>Participants independently rated their nausea severity on separate scales at the baseline and 30-minute evaluations to prevent the baseline VAS score from influencing the 30-minute mark. The VAS had the words &quot;Least Severe&quot; on the left and &quot;Most Severe&quot; on the right. The possible values range from 0 to 100mm with 0 at the &quot;Least Severe&quot; extreme and 100 at the &quot;Most Severe&quot; extreme. Investigators instructed the participant to draw a single vertical line through the point on the 100mm scale that corresponded to their nausea severity at the times of measurement (Baseline and 30 minutes).</description>
        <time_frame>Baseline and 30 minute assessments</time_frame>
        <population>Analysis was performed on all patients who received one of the four treatments and completed the 30-minute VAS assessment. The trial was anticipated to require 18 months to achieve full accrual of patients (n=600). Given that we were at 30% information fraction at 17 months, an unplanned interim analysis was done.</population>
        <group_list>
          <group group_id="O1">
            <title>Ondansetron</title>
            <description>Patients randomized to a single 2 milliliter (mL) Ondansetron 4 mg intravenous dosage administration treatment</description>
          </group>
          <group group_id="O2">
            <title>Metoclopramide</title>
            <description>Patients randomized to a single 2 mL Metoclopramide 10 mg intravenous dosage administration treatment</description>
          </group>
          <group group_id="O3">
            <title>Promethazine</title>
            <description>Patients randomized to a single 2 mL Promethazine 12.5mg intravenous dosage administration treatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients randomized to a single 2-mL isotonic sodium chloride Saline Placebo intravenous treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale (VAS) Score for Nausea. This Was Calculated by Subtracting the Patient's Reported Score on the 30 Minute VAS From the Patient's Reported VAS Score on Their Baseline VAS.</title>
          <description>Participants independently rated their nausea severity on separate scales at the baseline and 30-minute evaluations to prevent the baseline VAS score from influencing the 30-minute mark. The VAS had the words &quot;Least Severe&quot; on the left and &quot;Most Severe&quot; on the right. The possible values range from 0 to 100mm with 0 at the &quot;Least Severe&quot; extreme and 100 at the &quot;Most Severe&quot; extreme. Investigators instructed the participant to draw a single vertical line through the point on the 100mm scale that corresponded to their nausea severity at the times of measurement (Baseline and 30 minutes).</description>
          <population>Analysis was performed on all patients who received one of the four treatments and completed the 30-minute VAS assessment. The trial was anticipated to require 18 months to achieve full accrual of patients (n=600). Given that we were at 30% information fraction at 17 months, an unplanned interim analysis was done.</population>
          <units>millimeter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0" lower_limit="-43.0" upper_limit="-8.0"/>
                    <measurement group_id="O2" value="-30.0" lower_limit="-43.5" upper_limit="-20.0"/>
                    <measurement group_id="O3" value="-29.0" lower_limit="-46.5" upper_limit="-9.5"/>
                    <measurement group_id="O4" value="-16.0" lower_limit="-45.0" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that ondanestron is not more effective in reducing nausea than metoclopramide, promethazine or isotonic normal saline. The sample size was chosen to detect a 12-mm difference in VAS improvement between ondanestron and any other treatment arm (assuming a SD of 25mm) at 90% power and 0.01 alpha significance level. We chose the 0.01 alpha level following a Bonferroni type of correction so that the overall type I error rate is about 0.05.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Based on the aforementioned values, we calculated a sample size for each treatment arm of 131 patients. We increased this sample estimate to 150 per treatment arm (total of 600 patients) to account for anticipated study attrition. Based on an unplanned interim conditional power futility analysis done at 30% information fraction, the decision was made to end the trial early.The futility analysis found the observed differences were far less than what was deemed clinically important.</non_inferiority_desc>
            <p_value>0.16</p_value>
            <p_value_desc>Being aware of the multiple comparison issues, we deliberately chose the 0.01 alpha level following a Bonferroni type of correction so that the overall type I error rate is about 0.05.</p_value_desc>
            <method>Kruskal-Wallis</method>
            <method_desc>We computed the effect of the 3 treatments relative to ondansetron.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>12</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25</dispersion_value>
            <estimate_desc>Change in VAS score was calculated as (VAS 30 min - VAS baseline). We calculated the differences in median VAS reductions for each arm relative to ondansetron.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ondansetron</title>
          <description>Patients randomized to a single 2 milliliter (mL) Ondansetron 4 mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="E2">
          <title>Metoclopramide</title>
          <description>Patients randomized to a single 2 mL Metoclopramide 10 mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="E3">
          <title>Promethazine</title>
          <description>Patients randomized to a single 2 mL Promethazine 12.5mg intravenous dosage administration treatment</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Patients randomized to a single 2-mL isotonic sodium chloride Saline Placebo intravenous treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Sedation following treatment</sub_title>
                <description>Patients were asked whether they felt more fatigued or tired.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <description>Patient was asked if they are feeling abnormally restless or fidgety following drug administration?</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache following treatment</sub_title>
                <description>Patients were asked if they experienced a new headache following drug administration?</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at iv site following medication administration</sub_title>
                <description>Patients were asked if they experienced burning at the site of their intravenous catheter following drug administration.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination resulted in failure to meet our predetermined sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Tyler Barrett</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>6159360253</phone>
      <email>tyler.barrett@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

